Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, TRI

Myeloid Therapeutics to Provide Updates on its RNA Immunotherapies at Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024


CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage immunology company, today announced it will be providing updates on its RNA immunotherapies at multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, at the San Diego Convention Center.

Details follow:

Title: In vivo programming of natural killer cells and T cells using mRNA delivered cytotoxic chimeric antigen receptors
Date & Time: Monday Apr 8, 2024, 9:00 AM - 12:30 PM
Location: Poster Section 2
Session Category: Immunology
Session Title: CAR-NK, NK Engagers, and NK Modulators
Poster Board Number: 2
Published Abstract Number: 1319

Title: In vivo Immune Cell Programming Using mRNA-LNP Chimeric Antigen Receptors
Date & Time: Monday Apr 8, 2024, 9:00 AM - 12:30 PM
Location: Poster Section 2
Session Category: Immunology
Session Title: CAR-NK, NK Engagers, and NK Modulators
Poster Board Number: 4
Published Abstract Number: 1321

Title: Preclinical & clinical activity of autologous mRNA engineered chimeric antigen receptor monocytes for targeted cancer immunotherapy
Date & Time: Monday Apr 8, 2024, 1:30 PM - 5:00 PM
Location: Poster Section 39
Session Category: Clinical Research
Session Title: Adoptive Cellular Therapy 1
Poster Board Number: 18
Published Abstract Number: 3612

About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA. For additional information, please visit, https://www.myeloidtx.com/ and follow us on LinkedIn and X/Twitter.

To meet with Myeloid leadership at AACR 2024 please email: [email protected]

Investor Contact
Amy Conrad
Juniper Point
[email protected]

Media Contact
Jennifer Hanley
Ridge Hill Group
[email protected]

(PRNewsfoto/Myeloid Therapeutics)

 

SOURCE Myeloid Therapeutics, Inc.


These press releases may also interest you

at 11:50
Median Technologies, a World Leading Oncology Clinical Trial Imaging Services Provider, Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company
Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, "Median" or "The Company") (Paris:ALMDT) announced today that the Company has been selected as preferred vendor by a Top 3 pharmaceutical company, adding another...

at 11:47
Studies Reveal Cell-by-Cell Changes Caused When Pig Hearts and Kidneys are Transplanted into Humans
Surgical teams at NYU Langone Health performed the world's first genetically modified pig kidney transplants into a human body in September and November 2021, and then transplanted two pig hearts in the summer of 2022. These procedures were done in...

at 11:30
Wayspring Secures Minority Investment Led by CVS Health Ventures to Expand Innovative Substance Use Disorder (SUD) Home Program
Wayspring, a value-based care entity focused on substance use disorder (SUD) populations, today announced a capital raise led by CVS Health Ventures. The investment recognizes Wayspring's impactful approach to managing populations with SUD,...

at 11:28
HealthCentral Corp. Announces Oncology Site Rebrand
HealthCentral Corp. today announced a rebranding of its premier platform for oncologists, OBR Oncology, as Oncology News Central, reflecting the site's position as an essential hub for information and insights across the oncology landscape. ...

at 11:15
Genmab Completes Acquisition of ProfoundBio
Genmab A/S announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers in an all-cash...

at 11:08
Glooko Announces Presidents of Life Sciences and Connected Care
Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma and medical partners, proudly announces the appointments of Dr. David Pass and Adam Hameed as Presidents of Life Sciences and Connected Care,...

More news about Health...


News published on and distributed by: